Trials / Recruiting
RecruitingNCT06685978
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial of Efficacy and Safety of Xiangjurupining Capsule in the Treatment of Hyperplasia of Mammary Glands(Syndrome of Stagnation of Liver-qi and Phlegm)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 430 (estimated)
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).
Detailed description
Xiangjurupiling Capsule is an oral pure Chinese medicine preparation.This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xiang Ju Ru Pi Ning capsule Placebo | Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle. |
| DRUG | Xiang Ju Ru Pi Ning capsule | Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle. |
Timeline
- Start date
- 2024-04-26
- Primary completion
- 2026-04-30
- Completion
- 2026-07-31
- First posted
- 2024-11-13
- Last updated
- 2024-11-13
Locations
27 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06685978. Inclusion in this directory is not an endorsement.